Mechanical thrombectomy for cancer patients with leg blood clots
Clinical Comparative Study of Mechanical Thrombectomy and Simple Anticoagulation Therapy for Acute Lower Limb Deep Vein Thrombosis in Tumor Patients Under VTE Prevention and Control System
This study is testing a new procedure for treating leg blood clots in cancer patients to see if it works better than standard blood thinners.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | RenJi Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT06085495 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness and safety of improved mechanical thrombectomy (PMT) compared to traditional anticoagulation in treating acute lower limb deep vein thrombosis (DVT) in cancer patients. Fifty participants will be randomly assigned to either the PMT group or the control group, with clinical outcomes assessed at 3, 6, and 12 months post-treatment. Key evaluations will include vital signs, Doppler ultrasound results, quality of life scores, and any adverse events. The aim is to develop a new treatment strategy for DVT in cancer patients to enhance prevention and management of venous thromboembolism (VTE).
Who should consider this trial
Good fit: Ideal candidates are cancer patients aged 18 to 75 with acute lower limb DVT diagnosed within the last 14 days.
Not a fit: Patients with a history of DVT in the same limb or those with contraindications to thrombolytic drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve treatment outcomes for cancer patients suffering from acute DVT.
How similar studies have performed: While there is ongoing research in this area, this specific approach using PMT in cancer patients with DVT is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1) Between the ages of 18 and 75; 2) Suffering from acute lower limb deep vein thrombosis (DVT) with a duration of less than 14 days from onset; 3) Thrombosis involving the iliac vein, femoral vein, or popliteal vein; 4) The patient has been diagnosed with tumors, including benign or malignant tumors, including surgical or conservative treatment; 5) Sign an informed consent form. Exclusion Criteria: * 1) Patients with a history of deep vein thrombosis of the same lower limb in the past; 2) Patients with plasma Cr levels greater than 180umol/L; 3) Patients with contraindications to thrombolytic drugs; 4) Patients with concomitant inferior vena cava thrombosis or simple calf intermuscular vein thrombosis; 5) Patients who are known to be allergic to heparin, low molecular weight heparin, contrast agents, etc; 6) Patients who have participated in clinical trials of drugs or other medical devices that interfere with this clinical trial within the past 3 months; 7) Pregnant and lactating women; 8) Patients with a life expectancy of less than 6 months, or those with other diseases that may cause difficulty in testing or significantly shorten the patient's life expectancy (\<1 year), including severe liver disease, cardiac insufficiency, etc; 9) Patients with autoimmune thrombotic disease; 10) Patients who are unable or unwilling to participate in this trial.
Where this trial is running
Shanghai, Shanghai
- Renji Hospital — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Lei Lyu
- Email: wwxxyyzz@263.net
- Phone: 13917427119
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.